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Abstract
Background: Although parity and age at first pregnancy are among the most known extrinsic factors that
modulate breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in
depth. Recent data suggest that pregnancy-induced tumor protection is different according to breast cancer
subtypes, with parity and young age at first pregnancy being associated with a marked reduction in the risk of
developing luminal subtype but not triple negative breast cancer. In this study, we investigated the imprint of
parity and age at first pregnancy on the pattern of somatic mutations, somatic copy number alterations,
transcriptomic profiles, and tumor immune microenvironment by assessing tumor-infiltrating lymphocytes (TILs)
levels of subsequent breast cancer.
Methods: A total of 313 patients with primary breast cancer with available whole genome, RNA sequencing, and
TILs data were included in this study. We used a multivariate analysis adjusted for age at diagnosis, pathological
stage, molecular subtypes, and histological subtypes. We compared nulliparous vs. parous, late parous vs. early
parous, and nulliparous vs. pregnancy-associated breast cancer (PABC) patients. Late and early parous patients were
grouped by using the median age at first pregnancy. PABC was defined as patients diagnosed up to 10 years
postpartum.
Results: Genomic alterations of breast cancer were associated with age at first pregnancy but not with parity status
alone. Independently of clinicopathological features, early parous patients developed tumors characterized by a
higher number of Indels (Padj = 0.002), a lower frequency of CDH1 mutations (1.2% vs. 12.7%; Padj = 0.013), a higher
frequency of TP53 mutations (50% vs. 22.5%; Padj = 0.010), and MYC amplification (28% vs. 7%; Padj = 0.008). PABC
were associated with increased TILs infiltration (Padj = 0.0495).
Conclusions: These findings highlight an unprecedented link between reproductive history and the genomic
landscape of subsequent breast cancer. We further hypothesize that TP53-mutant premalignant lesions could be
less susceptible to the protective effect of an early parity, which might explain the difference of parity-induced
protection according to breast cancer subtypes. This work also advocates that reproductive history should be
routinely collected in future large-scale genomic studies addressing the biology of female cancers.
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Background
The effect of parity and age at first pregnancy on the risk
of developing breast cancer has been well documented
[1–5]. Parity is known to have a dual effect on breast
cancer risk with an increased risk during 5 to 10 years
after pregnancy, followed by a strong and life-long pro-
tective effect [1, 6]. This effect is strongly influenced by
age at first pregnancy as pregnancy-induced tumor pro-
tection is more pronounced if first pregnancy has oc-
curred early in life. Recent data suggest that
pregnancy-induced tumor protection is different accord-
ing to breast cancer subtypes, with parity and young age
at first pregnancy being associated with a marked reduc-
tion in the risk of developing luminal subtype tumors
[7–10].
Several studies have attempted to investigate the
mechanisms underlying this phenomenon [11, 12]. How-
ever, although parity and age at first pregnancy are
among the most known extrinsic factors that modulate
breast cancer risk, their impact on the biology of breast
cancer has never been explored in depth. We have previ-
ously observed that breast cancer diagnosed during
pregnancy has different biology at the genomic levels
[13]. In the present study, we used a systematic multi-
variate analysis to investigate the imprint of parity and
age at first pregnancy on the pattern of somatic muta-
tions, somatic copy number alterations (SCNAs), tran-
scriptomic profiles, and tumor-infiltrating lymphocytes
(TILs) levels in a series of 313 breast cancer patients




All analyses were performed on a publicly available data-
set comprising 560 breast cancer patients referred to as
BRCA560 [14]. Clinical data, sequencing coverage, and
mutational load were obtained from Additional file 1:
Table S1–S3 in that reference. Coding driver mutation
events and the contribution of mutational signatures
were obtained from Additional file 1: Table S14 and S21
in that reference. Raw count data from RNA sequencing
were obtained from the authors. Results from HRDetect
classifier were obtained from Additional file 1: Table S4
in reference [15].
Patients selection
Eligible patients from BRCA560 were those with samples
collected from primary tumor only (patients with local
recurrence or metastasis samples were excluded, n = 8)
who had available information on parity. There were
only two available HER2+ patients (both parous) in the
transcriptomic analysis so we preferred to exclude them
from this analysis. For each patient, we determined the
breast cancer intrinsic subtype (PAM50) using genefu R/
Bioconductor package [16]. Nulliparous patients were
defined as women with breast cancer who had no
full-term pregnancy at the time of breast cancer diagno-
sis. Parous patients were defined as women with breast
cancer who had at least one full-term pregnancy at the
time of breast cancer diagnosis. Early parous patients
were defined as ≤ 25 years of age at first full-term preg-
nancy, while late parous patients were defined as >
25 years of age at first full-term pregnancy. PABC pa-
tients were defined as women diagnosed not during
pregnancy but up to 10 years after the first pregnancy.
As referred to the publicly available BRCA560 dataset
[14], the Internal Review Boards of each participating in-
stitution approved the collection and use of samples of
all patients in this study.
TIL evaluation
The percentage of TILs was independently evaluated by
two pathologists (R.S. and H.M.H.) on hematoxylin and
eosin slides using the International TILs Working Group
2014 methodology as described before [17]. There were
242 original samples with evaluable TILs from 239 pa-
tients. For the three patients with two samples, the arith-
metic averages were obtained. We obtain a final set of
231 patients with primary tumor only (patients with
local recurrence or metastasis samples only were ex-
cluded, n = 8). TIL information for patients for which
evaluation from only one pathologist was available were
discarded (n = 3). The TILs were scored in the context of
an International Cancer Genome Consortium (ICGC)
project on the immune characterization of this series,
and the scoring is available for all institutions having the
ICGC Data Access Compliance Office (DACO) approval.
The data will be made broadly available when this global
project will be finished or before upon request to the
authors.
Statistical analysis
Except for age at diagnosis that was considered as a con-
tinuous variable and therefore compared using the
non-parametric Mann–Whitney U test, differences in
other clinicopathological characteristics of breast cancer
between groups were analyzed using the χ2 test or the
Fisher exact test when appropriate. All statistical tests
comparing groups were done using the non-parametric
Mann–Whitney U test and the χ2 test or the Fisher
exact test when appropriate for continuous and categor-
ical variables, respectively. For the multivariate analysis,
we used a linear and logistic regression to assess the in-
dependent association of continuous (log transformed)
and categorical variables respectively with—parity (nul-
liparous vs parous) or—age at first pregnancy (≤ 25 years
vs. > 25 years) controlling for age at diagnosis,
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pathological stage, molecular subtypes by IHC, and
histological subtypes. For WGS results, we also cor-
rected for log-transformed sequence coverage of tumor
and normal samples (continuous). All interaction and
multivariate tests (Padj) were done using the analysis of
variance to compare the models with and without the
extra term. Because continuous variables contain zeros,
the logarithmic transformation was applied as follows:
log10(x + 1). The Kruskal–Wallis test was used to test if
MYC expression originates from the same population
according to the status of MYC/TP53 alterations. All
correlations were calculated using the non-parametric
Spearman’s rho coefficient. All reported P values were
two-tailed. Multiple testing correction was performed
using the false discovery rate method (FDR) [18], and
differences were considered significant when the FDR
was < 0.05. All analyses were done in R software version
3.3.3 (available at www.r-project.org) and Bioconductor
version 3.6. Differential expression analysis was per-
formed with DESeq2 v.1.14.1 R/Bioconductor package
[19] on raw count data (20,724 genes). Significantly dif-
ferentially expressed genes were selected with a FDR of
< 0.1, independent filtering was performed using default
parameters to select a set of genes for multiple test cor-
rection which maximizes the number of adjusted P
values less than a given critical value alpha (by default
0.1) and differentially expressed genes were identified by
using the default cutoff of P value adjusted for multitest-
ing < 0.1. We used gage v.2.24.0 R/Bioconductor package
[20] to identify significantly enriched pathways from the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
[21] and biological process from Gene Ontology with
the log2FoldChange from DEseq2 results as input data.
Results
Association between clinicopathological variables, parity,
and age at first pregnancy
From a publicly available dataset comprising 560 breast
cancer patients [14], a total of 313 with available infor-
mation on parity were included. We identified 264
(84.3%) parous and 49 (15.7%) nulliparous patients
(Additional file 2: Figure S1). In the parous group, 153
patients (57.9%) had available information on age at first
pregnancy (median of 25 years, range 16–46 years). Par-
ous patients were divided into two groups: 82 early and
71 late parous patients by using the median age at first
pregnancy as a cutoff value. All patients had available
somatic mutations and SCNAs data, 182 patients
(58.1%) had available transcriptomic data, and 170 pa-
tients (54.3%) had information on TIL levels (Add-
itional file 2: Figure S2).
Table 1 summarizes the clinicopathological features of
patients. Compared to parous patients, nulliparous pa-
tients had larger tumors (tumor size > 2 cm, 59.2% vs.
37.1%, P = 0.006), higher frequency of lymph node posi-
tive disease (40.8% vs. 27.7%; P = 0.027), and lower fre-
quency of triple negative breast cancer (TNBC) (4.1% vs.
23.2%; P = 0.001). Compared to early parous patients,
late parous patients had a younger age at breast cancer
diagnosis (median, 49 years; range, 28–81 years vs. me-
dian, 59 years; range, 34–81 years; P = 2.58 × 10−5) and
were more often pre-menopausal (45.3% vs. 20.9%; P =
0.005). Late parous patients also had smaller tumors
(tumor pathological size > 2 cm, 40.8% vs. 51.2%, P =
0.012), lower frequency of TNBC (19.7% vs. 39%, P =
0.026), and higher frequency of lobular histological sub-
type (14.5% vs. 2.5%, P = 0.01).
In the following sections, we investigated the imprint
of parity and age at first pregnancy on breast cancer
biology by using a systematic multivariate analysis ad-
justed for potential confounders, namely age at diagno-
sis, pathological stage, molecular subtypes by IHC, and
histological subtypes.
The influence of parity and age at first pregnancy on the
mutational landscape of breast cancer
We first sought to investigate the imprint of parity and
age at first pregnancy on somatic mutational load (Add-
itional file 1: Table S1). There was no significant differ-
ence in the total number of substitutions (SNVs)
according to parity nor age at first pregnancy (Padj =
0.097, Padj = 0.075, respectively, Fig. 1a). There was no
significant difference in the total number of insertions or
deletions (Indels) according to parity (Padj = 0.464,
Fig. 1a). In contrary, compared to tumors from late par-
ous patients, tumors from early parous patients were sig-
nificantly associated with a higher Indels load (Padj =
0.002, FDR = 0.007, Fig. 1a). There was no significant dif-
ference between the total number of rearrangements ac-
cording to parity nor age at first pregnancy
(Additional file 1: Table S1).
We next interrogated the influence of parity and age
at first pregnancy on the frequency of mutations in
breast cancer driver genes. Among the driver mutated
genes, seven had at least one non-silent mutation with a
frequency of > 5% across the whole cohort (Add-
itional file 1: Table S2). As expected, PIK3CA and TP53
were the most frequently mutated genes (Fig. 1b). None
of the driver mutated genes were associated with parity
in the multivariate analysis. However, in the parous
group, early age at first pregnancy was independently as-
sociated with higher frequency of TP53 mutations (41/
82 (50%) vs. 16/71 (22.5%); Padj = 0.010; FDR = 0.046,
Fig. 1b) and lower frequency of CDH1 mutations (1/82
(1.2%) vs. 9/71 (12.7%); Padj = 0.013; FDR = 0.046, Fig. 1b).
Considering the distribution of TP53 mutations type,
early parous patients had a significantly higher frequency
of truncating mutations as compared to late parous
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patients (21/82 (25.6%) vs. 5/71 (7%); Padj = 0.014, Add-
itional file 2 : Figure S3). Altogether, our results show
that age at first pregnancy is associated with biological
differences in the mutational landscape of subsequent
breast tumors with early parity associated with higher
Indels burden and higher frequency of deleterious muta-
tions in TP53 gene.
The influence of parity and age at first pregnancy on
somatic copy number alterations
Somatic copy number alterations (SCNAs) play a major
role in breast cancer biology [22, 23]. We identified five
driver genes with a frequency of SCNAs > 5% across all
patients (Additional file 1: Table S3). MYC tended to be
more frequently amplified in parous than in nulliparous
patients (49/264 (18.6%) vs. 2/49 (4.1%); Padj = 0.052;
FDR = 0.26, Fig. 1b). In the parous group, MYC amplifi-
cation was significantly more frequent in the early par-
ous group than in the late parous group (23/82 (28%) vs.
5/71 (7%); Padj = 0.008; FDR = 0.040, Fig. 1b). When
evaluating the co-occurrence of SCNAs and somatic
mutations, we found that co-occurrence of MYC ampli-
fication and TP53 mutations was independently associ-
ated with age at first pregnancy, with early parous
patients having a higher frequency of simultaneous alter-
ations of MYC and TP53 genes (15/82 (18.3%) vs. 3/71
(4.2%); Padj = 0.087, Fig. 2a and Additional file 2: Figure
S3). Taken together, these results suggest that age at first
Table 1 Clinicopathological features of nulliparous and parous patients
N Nulliparous Parous P Early parous Late parous P
49 264 82 71
Age at diagnosis 54 (30–81) 55 (28–81) 0.796a 59 (34–81) 49 (28–81) 2.6 × 10–5a
Menopausal status
Pre 13 (33.3%) 60 (30.3%) 0.85 14 (20.9%) 29 (45.3%) 0.0053
Post 26 (66.7%) 138 (69.7%) 53 (79.1%) 35 (54.7%)
Stage
I 7 (14.9%) 41 (15.9%) 0.019 6 (7.6%) 17 (24.3%) 0.039
II 20 (42.6%) 81 (31.4%) 33 (41.8%) 27 (38.6%)
III 11 (23.4%) 30 (11.6%) 12 (15.2%) 10 (14.3%)
IV 0 (0%) 1 (0.4%) 1 (1.3%) 0 (0%)
Na 9 (19.1%) 105 (40.7%) 27 (34.2%) 16 (22.9%)
pT
Tx 9 (18.4%) 105 (39.8%) 0.0062 27 (32.9%) 16 (22.5%) 0.012
≤ 2 cm 11 (22.4%) 61 (23.1%) 13 (15.9%) 26 (36.6%)
> 2 cm 29 (59.2%) 98 (37.1%) 42 (51.2%) 29 (40.8%)
pN
Nx 11 (22.4%) 112 (42.4%) 0.027 30 (36.6%) 17 (23.9%) 0.2
N0 18 (36.7%) 79 (29.9%) 25 (30.5%) 23 (32.4%)
N1+ 20 (40.8%) 73 (27.7%) 27 (32.9%) 31 (43.7%)
Grade
I 6 (14%) 29 (12.7%) 0.93 8 (9.8%) 5 (7%) 0.059
II 17 (39.5%) 86 (37.7%) 25 (30.5%) 35 (49.3%)
III 20 (46.5%) 113 (49.6%) 49 (59.8%) 31 (43.7%)
Subtype by IHC
Lum A-like 22 (44.9%) 106 (40.3%) 0.0013 29 (35.4%) 39 (54.9%) 0.026
Lum B-like 19 (38.8%) 54 (20.5%) 20 (24.4%) 17 (23.9%)
HER2+/HR+ 6 (12.2%) 29 (11%) 0 (0%) 0 (0%)
HER2+/HR- 0 (0%) 13 (4.9%) 1 (1.2%) 1 (1.4%)
TNBC 2 (4.1%) 61 (23.2%) 32 (39%) 14 (19.7%)
Histology
Ductal 36 (76.6%) 203 (81.2%) 0.67 71 (88.8%) 49 (71%) 0.01
Lobular 5 (10.6%) 23 (9.2%) 2 (2.5%) 10 (14.5%)
Other 6 (12.8%) 24 (9.6%) 7 (8.8%) 10 (14.5%)
pT pathological tumor size, pN pathological nodal status, HR hormone receptor, P P value derived from χ2 test or the Fisher exact test when appropriate
aExcept continuous variable derived from Mann–Whitney U test
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a b c d
Fig. 1 Imprint of pregnancy and age at first pregnancy on breast cancer biology. a Comparison of somatic SNVs and Indels in tumor between
nulliparous (n = 49) and parous (upper) (n = 264) and between early (n = 82) and late parous (bottom) (n = 71). Padj, P values derived from
multivariate linear regression analysis adjusted for potential confounders. b Radar plots showing the frequency of somatic driver mutations and
somatic driver SNCAs in breast cancer from nulliparous (n = 49) and parous (upper) (n = 264) and between early (n = 82) and late parous
(bottom) (n = 71) patients. Significant genes independently associated with parity or age at first pregnancy are highlighted in bold. c Proportion
of PAM50 breast cancer subtypes in nulliparous (n = 34) and parous (upper) (n = 148) and in early (n = 51) and late parous (bottom) (n = 45)
patients. d Comparison of TIL levels (%) between nulliparous (n = 26) and parous (upper) (n = 134) and between early (n = 47) and late parous
(bottom) (n = 38) patients. Padj, P values derived from multivariate linear regression analysis adjusted for potential confounders
a b c
Fig. 2 Co-occurrence of MYC amplification and TP53 mutations is associated with age at first pregnancy. a Timeline of 153 patients with available
data on age at first pregnancy. Each line represents an individual patient from age at first pregnancy (start of the line) to age at breast cancer
diagnosis (end of the line). Late parous patients (upper) (n = 71) and early parous patients (bottom) (n = 82) are grouped according to median
age at first pregnancy (25 years). Gray diamond represents the median age at first pregnancy and at diagnosis in the two groups. Lines are
colored according to TP53 mutations (green) MYC amplification (dark red) and the co-occurrence of both (red). b Comparison of MYC expression
in early (n = 51) and late parous patients (n = 45). Each dot represents an individual patient and is colored according to TP53 mutations (green)
MYC amplification (dark red) and the co-occurrence of both (red). P value is derived from the multivariate linear regression analysis adjusted for
potential confounders. c MYC expression according to TP53 mutations, MYC amplification or the co-occurrence of both. P value is derived from
the Kruskal–Wallis test
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pregnancy may also shape the somatic copy number al-
teration profiles of subsequent breast cancer.
The influence of parity and age at first pregnancy on
BRCAness
We investigated the BRCAness status of tumors accord-
ing to reproductive history. Since germline BRCA1/2
mutation status was not available for all samples, we
used HRDetect to identify BRCA1/BRCA2-deficient
samples [15]. We did not find any significant differences
in the proportion of BRCA1/BRCA2-deficient patients
between nulliparous and parous groups (6/49 (12.2%) vs.
50/264 (18.9%), respectively, Padj = 0.386) nor between
early and late parous group (25/82 (30.5%) vs. 14/71
(19.7%), respectively, Padj = 0.473). Thus, reproductive
history and age at first pregnancy do not seem to affect
homologous recombination DNA repair capacity in sub-
sequent breast cancer.
Integrative analysis of the genomic alterations and the
transcriptomic profiles associated with parity and age at
first pregnancy
RNA sequencing data were available for a subset of 182
patients, of which 34 were nulliparous (Additional file 2:
Figure S2 and Additional file 1: Table S4). We first deter-
mined the intrinsic molecular subtype distribution of
breast cancer using the PAM50 classifier [24]. We did
not find a significant difference in the distribution of the
PAM50 subtypes between nulliparous and parous
(Fig. 1d). In contrast, early parous patients had a higher
proportion of basal-like subtype tumors (15/51 (29.4%)
vs. 4/45 (8.9%); P = 0.009, Fig. 1d, Additional file 1: Table
S4). In order to identify de novo gene expression profiles
that might be associated with parity and age at first
pregnancy, we performed a multivariate differential ex-
pression analysis using DEseq2 [19] controlling for age
at diagnosis, pathological stage, molecular subtypes by
IHC, and histological subtypes. A total of 62 genes were
differentially expressed between nulliparous and parous
(Additional file 1: Table S5). Among these genes, three
were associated with mammary development; OXTR and
ATP2B2 were downregulated whereas NRG3 was upreg-
ulated in nulliparous. Pathway analysis using the gener-
ally applicable gene-set enrichment (GAGE) analysis
[20] revealed an enrichment of genes related to extracel-
lular matrix (ECM) receptor interaction in parous (Add-
itional file 1: Table S6). When comparing early and late
parous patients, 466 genes were differentially expressed,
among which 305 were upregulated in early parous
(Additional file 1: Table S7). However, pathway analysis
did not reveal any significant enrichment of relevant bio-
logical processes (Additional file 1: Table S8).
Due to the higher frequency of MYC amplification in
early parous patients, we determined if this would also
impact MYC at the mRNA expression levels. Early par-
ous patients were independently associated with an up-
regulation of MYC expression (Padj = 0.0113, Fig. 2b).
We also evaluated the expression of MYC according to
TP53 mutations and MYC amplification and found that
MYC expression was the highest in tumors harboring
concurrent TP53 mutation and MYC amplification
(Fig. 2c).
The influence of parity and age at first pregnancy on
tumor immune microenvironment
Previous reports have hypothesized that the
pregnancy-induced tumor protection could be attribut-
able to an improved anti-tumor immunity [25–29].
Therefore, we assessed whether reproductive history
could be associated with tumor-infiltrating lymphocyte
(TIL) levels that is considered as a surrogate of tumor
immunogenicity (Additional file 1: Table S9). We did
not find any significant difference in the proportion of
stromal TILs according to parity or according to the age
at first pregnancy (Padj = 0.655; Padj = 0.200, respectively,
Fig. 2d). Similarly, no differences were observed when
comparing intratumoral TILs according to parity or age
at first pregnancy (Padj = 0.240; Padj = 0.889, Add-
itional file 1: Table S9). Thus, reproductive history does
not seem to influence breast tumor immune
microenvironment.
Pregnancy-associated breast cancer is associated with
increased TIL infiltration
Pregnancy-associated breast cancer (PABC) can be de-
fined as cases diagnosed up to 10 years postpartum [30].
In this cohort, we identified 17 PABC patients and com-
pared them with 49 nulliparous patients. Compared to
nulliparous, PABC patients had a younger age at diagno-
sis (median, 38 years; range, 28–48 years vs. median, 54
years; range, 30–81 years; P = 5.79 × 10−6, Additional file 1:
Table S10) and higher frequency of TNBC (5/17 (29.4%)
vs. 2/49 (4.1%); P = 0.021, Additional file 1: Table S10).
We did not find any significant differences between
PABC and nulliparous in the pattern of somatic muta-
tions or somatic copy number alterations (Add-
itional file 1: Table S1-S3). Nine PABC had available
gene expression and TIL scoring. At the transcriptomic
level, we found that PABC patients were associated with
enrichment of biological processes related to immune
function (Fig. 3a and Additional file 1: Table S11). More-
over, PABC patients had an increased lymphocytic infil-
tration both for stromal and intratumoral TIL levels
(Padj = 0.040 and Padj < 0.0001, respectively; Fig. 3b, c).
Taken together, these results indicate that cancer occur-
ring in the postpartum breast is associated with in-
creased TIL levels.
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Discussion
To our knowledge, this is the first study that explores
the impact of reproductive history on the genomic land-
scape and the immune composition of subsequent breast
cancer. While previous studies documented the risk of
developing breast cancer according to reproductive his-
tory [1–5], this analysis provides further insights on the
differences at the pathologic, genomic, transcriptomic,
and immunologic levels according to prior parity and
age at first pregnancy. Independently of clinicopathologi-
cal features, our findings indicate that age at first preg-
nancy impacts the genomic makeup of subsequent
breast cancer. Early parous patients developed tumors
characterized by a higher number of Indels, a lower fre-
quency of CDH1 mutations, a higher frequency of TP53
mutations and MYC amplification, while PABC patients
exhibited higher TIL infiltration.
The higher proportion of TNBC in parous and par-
ticularly in early parous patients could be attributed to a
differential effect of pregnancy-induced tumor protec-
tion according to breast cancer subtypes. We and others
have documented that the pregnancy-induced tumor
protection is different according to breast cancer sub-
types with parity and young age at first pregnancy being
associated with a marked reduction in the risk of devel-
oping luminal subtype [7–10].
Our study reveals that age at first pregnancy has a big-
ger imprint on genomic alterations of breast cancer than
parity status alone. The apparent lack of impact of parity
per se could be due to the relatively low number of nul-
liparous patients. An alternative explanation could be
that breast cancer from late parous resembles breast
cancer from nulliparous women. Therefore, the lack of
difference between nulliparous and parous could be re-
lated to the fact that the parous group encompasses late
parous patients resulting in a possible dilution of the
signal.
At the gene level, early parous patients had a higher
frequency of TP53 mutation, MYC amplification, and a
lower frequency of CDH1. Interestingly, the
co-occurrence of TP53 mutations and MYC amplifica-
tion was independently associated with age at first preg-
nancy, while the proportion of truncating TP53
mutations was higher in early parous patients. We ob-
served that tumors harboring concurrent MYC amplifi-
cation and TP53 mutation had the highest MYC
expression. This observation is in line with a recent in-
vestigation of the MYC oncogene in pan-cancer data
[31]. Previous reports have suggested that TP53 muta-
tions are a common mechanism that disturbs the apop-
totic pathway in MYC-driven tumors [32]. It has been
hypothesized that overexpression of MYC induces
TP53-dependent apoptosis, and, as a consequence,
MYC-driven tumors often require dysregulation of the
apoptotic pathway to promote proliferation [33]. TP53
has long been recognized as a potential mediator of
pregnancy-induced resistance to mammary carcinogen-
esis. It has been shown in mice that p53 and its down-
stream transcriptional target p21 are increased in parous
and estrogen/progesterone-treated mammary epithelium
in response to a carcinogen [34]. In the absence of p53,
the protection given by parity or exogenous hormones is
a b c
Fig. 3 PABC patients are associated with higher TIL levels. a Results from the GAGE analysis showing the top 20 most significant biological
processes enriched in PABC patients. b Comparison of stromal and c intratumoral (right) TIL levels (%) between nulliparous (n = 49) and PABC
(n = 17). Padj, P values derived from multivariate linear regression analysis adjusted for potential confounders
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lost [35–37]. We hypothesize that the higher frequency
of TP53-mutant breast cancer observed in early parous
women could be explained by the fact that an early preg-
nancy could protect less effectively against TP53 mutant
pre-malignant lesions (Fig. 4). In breast cancer, TP53
mutations are highly linked to molecular subtype with a
frequency of 80% in basal-like compared to 26% in lu-
minal tumors [23]. The lower susceptibility of TP53-mu-
tant premalignant lesions to the protective effect of an
early parity might be the underlying cause of the known
differential effect of parity-induced protection according
to tumor subtypes.
CDH1 mutations have been associated with invasive
lobular breast cancer subtype [38]. As the multivariate
analysis was adjusted for histological subtypes, the lower
frequency of CDH1 mutations observed in early parous
patients cannot be explained by differences in histo-
logical subtypes. Finally, in line with prior studies [39,
40], our data do not show an impact of parity and age at
first birth on BRCA-related breast cancer risk.
Another hypothesis underlying the protection associ-
ated with an early pregnancy argues that the high level
of circulating hormones associated with pregnancy
would induce differentiation of the mammary gland
while decreasing the tumorigenic potential of breast cells
[41]. Gene expression studies comparing nulliparous and
parous normal mammary tissue, from both rat and hu-
man, have observed upregulation of genes related to cell
differentiation in the parous breast [42, 43]. According
to this theory, a full-term pregnancy early in reproduct-
ive life would induce a molecular switch in mammary
stem cells leading to a permanent decrease in their pro-
liferation potential and resistance to oncogenic trans-
formation [11, 44]. The results from our bulk RNA-seq
analysis of tumor samples are not in line with this hy-
pothesis, but we believe that future studies using
single-cell RNA-seq would improve our understanding
of the mechanism of the parity-induced protection
against breast cancer. Noteworthy, we found that the ex-
pression of OXTR was higher in parous compared to
nulliparous patients. In the normal tissue of parous
women, the gene encoding oxytocin receptor (OXTR) is
physiologically upregulated during lactation and has
been shown to remain overexpressed later in life [12,
45]. However, due to the lack of functional studies, it is
not clear whether this gene is involved in breast cancer
tumorigenesis or simply related to physiological changes
induced by pregnancy. The enrichment of genes related
to ECM receptor interaction in parous patients might be
related to involution, a profound physiological change in
the mammary gland after pregnancy. Right after breast-
feeding the fully differentiated gland regresses to its
pre-pregnant state by an innate tissue-remodeling mech-
anism. Evidence indicates that involution is mediated in
part by ECM-degrading proteinases, leading to basement
membrane degradation and subsequent apoptosis of the
unwanted secretory epithelial cells [46, 47]. The exact
role of the enrichment of genes related to ECM in par-
ous patients on human breast cancer biology has still to
be determined, but involution, that shares similarities
with inflammation and wound healing programs, has
been shown to promote breast cancer progression and
metastasis in several animal models [46, 48].
Finally, previous reports have hypothesized that the
pregnancy-induced tumor protection could be attributable
to an improved anti-tumor immunity [25–29]. Our ana-
lysis reveals no differences in TILs infiltration levels ac-
cording to parity or age at first pregnancy. The existence
of a more complex immune component related to repro-
ductive history cannot be excluded, but it is not supported
by our analysis. Previous reports have documented that
the immune milieu of the postpartum mammary gland as-
sociated with involution could promote tumorigenesis
[49–51]. We observed an increase of TILs levels in PABC
patients but the composition of the immune infiltrate has
still to be determined to validate this hypothesis.
A potential limitation of our study is the lack of data
on other reproductive factors (e.g., breastfeeding, age at
menarche, and time since last pregnancy) that could also
potentially imprint the biology of breast cancer. Indeed,
Fig. 4 Proposed model explaining the difference of parity-induced protection according to breast cancer subtypes. TP53 has long been
recognized as a potential mediator of pregnancy-induced resistance to mammary carcinogenesis. We hypothesize that an early pregnancy might
protect less effectively against TP53 mutant premalignant lesion. TP53 mutations are highly linked to the TNBC subtype; this could explain why
the pregnancy-induced resistance is lost in TNBC
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breastfeeding and age at menarche have been linked to
breast cancer risk but since they are often self-reported,
they are more difficult to assess reliably [7]. The lack of
validation using an independent cohort is another import-
ant limitation. We retrieved the clinical information from
the three independent cohorts of breast cancer with pub-
licly available genomic data [23, 52, 53], but unfortunately,
reproductive variables were missing, which precluded the
validation of our findings. Another limitation is the ab-
sence of HER2+ subtype in the transcriptomic analysis.
Conclusions
In conclusion, our findings highlight an unprecedented
link between reproductive factors and the genomic land-
scape of subsequent breast cancer. We further
hypothesize that TP53-mutant premalignant lesions
could be less susceptible to the protective effect of an
early parity, which might explain the difference of
parity-induced protection according to breast cancer
subtypes. Our results that need to be validated in other
studies support that patients’ reproductive history
should be routinely collected in future large-scale gen-
omic studies addressing the biology of female cancers.
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